← Back to headlines
Roivant Anticipates FDA Approval for New Skin Disease Drug
Roivant Chief Executive Officer Matt Gline expects the FDA to approve the launch of a new drug designed to combat a debilitating skin disease, with plans for it to be on the market by September.
6 Aug, 15:37 — 6 Aug, 15:37


